Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameAkeso
Stock Code09926
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities臨床階段生物製藥公司,致力於首創及同類最佳療法的自主發現、開發及商業化,專注於腫瘤、免疫及其他治療領域的未決醫療需求。
Listing Date2020-04-24
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)廣東省中山市火炬開發區神農路6號
Business Address (Hong Kong)香港 銅鑼灣 希慎道33號 利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteakesobio.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 16.18 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 16,180
Par ValueTo be extracted
Offer Period2020-04-14 to 2020-04-17
Global Offering Shares159,500,000 shares
HK Public Offer Shares (Initial)15,950,000 shares (10.0%)
Public Offer Lots (Initial)15,950lots (Pool A7,975lots,Pool B7,975lots)
International Placing Shares (Initial)143,545,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO763,133,176 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share49.3%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 2,580,710,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 16,180
2 lots 2,000 HK$ 32,360
3 lots 3,000 HK$ 48,540
4 lots 4,000 HK$ 64,720
5 lots 5,000 HK$ 80,900
6 lots 6,000 HK$ 97,080
7 lots 7,000 HK$ 113,260
8 lots 8,000 HK$ 129,440
9 lots 9,000 HK$ 145,620
10 lots 10,000 HK$ 161,800
15 lots 15,000 HK$ 242,700
20 lots 20,000 HK$ 323,600
25 lots 25,000 HK$ 404,500
30 lots 30,000 HK$ 485,400
35 lots 35,000 HK$ 566,300
40 lots 40,000 HK$ 647,200
45 lots 45,000 HK$ 728,100
50 lots 50,000 HK$ 809,000
60 lots 60,000 HK$ 970,800
70 lots 70,000 HK$ 1,132,600
80 lots 80,000 HK$ 1,294,400
90 lots 90,000 HK$ 1,456,200
100 lots 100,000 HK$ 1,618,000
150 lots 150,000 HK$ 2,427,000
200 lots 200,000 HK$ 3,236,000
250 lots 250,000 HK$ 4,045,000
300 lots 300,000 HK$ 4,854,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
350 lots 350,000 HK$ 5,663,000
400 lots 400,000 HK$ 6,472,000
450 lots 450,000 HK$ 7,281,000
500 lots 500,000 HK$ 8,090,000
600 lots 600,000 HK$ 9,708,000
700 lots 700,000 HK$ 11,326,000
800 lots 800,000 HK$ 12,944,000
900 lots 900,000 HK$ 14,562,000
1,000 lots 1,000,000 HK$ 16,180,000
2,000 lots 2,000,000 HK$ 32,360,000
3,000 lots 3,000,000 HK$ 48,540,000
4,000 lots 4,000,000 HK$ 64,720,000
5,000 lots 5,000,000 HK$ 80,900,000
6,000 lots 6,000,000 HK$ 97,080,000
7,000 lots 7,000,000 HK$ 113,260,000
7,975 lots 7,975,000 HK$ 129,035,500

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 93.7B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 12,347,494,787
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损人民币346.5百万元
Period-End Cash Balance人民币1,186.0百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019
Revenue 2,82670,879
Cost of sales 00
Gross profit 2,82670,879
Other income and gains, net 27,04550,186
Administrative expenses -20,157-55,421
Operating profit -151,708-340,718
Net finance costs -2,646-5,736
Profit before tax -154,354-346,454
Income tax expense 00
Profit for the year -154,354-346,454
Profit attributable to owners -142,307-335,386
Balance Sheet
Item 20182019
Cash and cash equivalents 313,7161,186,044
Inventories 16,96915,523
Total current assets 457,5171,255,964
Total assets 651,7181,672,939
Total current liabilities 86,236119,761
Total liabilities 163,6231,457,234
Total equity 488,095215,705
Equity attributable to owners 441,216-6,353
Interest-bearing borrowings 58,560211,375
Cash Flow Statement
Item 20182019
Net cash from operating activities -123,417-219,595
Net cash from investing activities -26,365-127,894
Net cash from financing activities 246,4281,230,192
Net increase in cash 96,646882,703
Depreciation of PP&E 10,44313,419
Depreciation of right-of-use assets 2,4822,964
Amortisation of intangible assets 46109
Purchase of PP&E -72,698-136,273
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 24.3
First Day OpenHK$ 23.5
First Day Change50.19%
First Day Volume98779200.0
First Day Turnover2372500000.0
Use of Proceeds
1、約75.0%,或1,827.7百萬港元,將主要用于以下產品研發及商業化; 2、約15.0%,或365.5百萬港元,將用于在中國廣州及中山發展生產及研發設施,其中大部分將用于購買新機器、儀器及設備以及擴展生產設施; 3、約10.0%,或243.7百萬港元,將用于我們的一般公司及營運資金用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Far East) Limited CE AAB026
Overall Coordinators (4)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 交银国际证券有限公司 CE APJ121 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (7)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 交银国际证券有限公司 CE APJ121 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 BOCI ASIA LIMITED CE AET863 CMB International Capital Holdings Corporation Limited CE AJB801 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Lead Managers (7)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 交银国际证券有限公司 CE APJ121 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 BOCI ASIA LIMITED CE AET863 CMB International Capital Holdings Corporation Limited CE AJB801 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 AIHC Master Fund 39,042,340 HKD — 1.51% — 6 months 2020-10-24
2 Boyu Capital Opportunities Master Fund 78,084,680 HKD — 3.03% — 6 months 2020-10-24
3 CRF Investment Holdings Company Limited 39,042,340 HKD — 1.51% — 6 months 2020-10-24
4 Fidelity International 507,615,140 HKD — 19.67% — 6 months 2020-10-24
5 Hankang Biotech Fund I, L.P. 23,428,640 HKD — 0.91% — 6 months 2020-10-24
6 Hudson Bay Master Fund LTD 78,084,680 HKD — 3.03% — 6 months 2020-10-24
7 Lake Bleu Prime Healthcare Master Fund Limited 351,429,600 HKD — 13.62% — 6 months 2020-10-24
8 OrbiMed Funds 117,143,200 HKD — 4.54% — 6 months 2020-10-24
9 中国国有企业结构调整基金股份有限公司 39,042,340 HKD — 1.51% — 6 months 2020-10-24

Directors & Management

PositionChinese nameEnglish Name
Chairman夏瑜—
Company Secretary席曉捷、陳芃霏—
No director data available.

Major Shareholders

Major Shareholders & Holdings夏瑜博士(约16.56%)、李百勇博士(约7.16%)、王忠民博士(约6.19%)、Waterband Limited(代表张鹏博士家族信托,约4.58%)为控股股东及主要股东。
About this page

This page shows Akeso (09926) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect